drugset / Trial / NCT02617810

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

NCT02617810

Phase 1 Completed 18 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate effect of multiple-dose administration of JNJ-42847922 on the single-dose pharmacokinetics of oral midazolam and single-dose pharmacokinetics and pharmacodynamics of (R)- and (S)-warfarin after oral administration of racemic warfarin.

Timeline

Start
2015-11
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 4 mg Oral
Subject Seltorexant Small molecule 20 mg Oral
Subject Warfarin Small molecule 25 mg Oral

Indications

No indication recorded.